Opens in a new tab
Lean Seal ISO website iv removebg
ALWAYS AUDIT READY
Feasibility Inquiry

Investigational Product Evolution – Are Your Site Qualification Approaches Keeping Pace?

Investigational Product Evolution
Share

The evolution of investigational products—moving from traditional cytotoxic chemotherapy to complex targeted therapies, immuno-oncology, and cell/gene therapies—has forced a shift in oncology site qualification from a focus on high-volume, general oncology capacity to specialized, infrastructure-intensive, and molecular-driven capabilities. Oncology trials are even more complex, longer, and more biomarker intensive than other therapeutic areas.

This is a shift in oncology trials from traditional, large-scale, studies to adaptive, biomarker-driven, and more patient-centric designs aimed at evaluating precision medicine, such as Antibody-Drug Conjugates (ADCs), CAR-T, and targeted therapies. Driven by the need to match specific tumor molecular profiles with targeted compounds has led to more complex and master protocols, basket trials, and expansion cohorts that allow for faster, more flexible, and efficient evaluation of efficacy and safety.

Key impacts on site selection include the need for specialized handling (e.g., cryogenic storage for CAR-T), advanced molecular diagnostics (NGS), and multidisciplinary teams to manage unique, often severe, adverse events.

To address these challenges, there is a growing, industry-wide push towards incorporating real-world evidence (RWE), utilizing international collaborations to increase recruitment, and fostering earlier, continuous interaction with regulatory agencies.

New Challenges Facing Sites

Investigators and research teams participating in clinical trials must deal with complex investigational products, study designs, and research environments. The emergence of new drug delivery systems and investigational products combining more than one drug, and the development of bio drugs such as monoclonal antibodies, peptides, siRNA, and gene therapy to treat disease constitute a new challenge for investigators and clinical sites.

At all sites participating in clinical trials, standard operating procedures (SOPs) for drug and drug delivery systems management are required. Under which all steps should be auditable, including reception, validation, storage, access, preparation, distribution, techniques of administration, use, return, and destruction of research products. Bio drugs require traceability and specific SOPs on the management of potential immune reactions. Investigational products must be stored under standard auditable conditions. The traceability of storage conditions (including temperature) requires these conditions be continuously monitored, and a dedicated space with restricted access limited to authorized qualified personnel facilitates the monitoring.

Key Factors Impacting Site Selection

  • Focus on specialized infrastructure to address the need for specialized handling (e.g., cryogenic storage for CAR-T).
  • Site qualification must verify staff are trained for the specific, complex handling requirements of new products and protocols. With advanced molecular diagnostics (NGS), and multidisciplinary teams to manage unique, often severe, adverse events.
  • Early phase sites that can quickly generate high-quality, complex data are prioritized for the increasing number of more targeted agents.

Site qualification now requires auditing cold-chain management and cell-thawing capabilities. The shift to advanced therapy medicinal products (ATMPs) requires sites have sophisticated logistics (e.g., vapor-phase liquid nitrogen storage) and specialized, sterile, and often certified pharmacy capabilities for handling cell modifications.

Molecular diagnostic capabilities are critical for site selection when seeking patient enrollment in “basket” or “umbrella” trials. With the rise of targeted and precision medicine, site qualification includes assessing on-site or high-quality off-site Next-Generation Sequencing (NGS) capabilities to rapidly identify biomarkers.

The rise of immunotherapy (IO agents) requires sites with specialized knowledge in managing immuno-related adverse events (irAEs) and cytokine release syndrome (CRS), necessitating a stronger focus on the PI and Clinical Site team’s experience in that specific modality.

Real-time data driven selection that makes use of targeted, data-driven approaches to identify, recruit, and retain patients is ever more important with the increasing complexity of products reducing reliance on traditional high-volume approaches.

Best Therapeutic Recruitment Trial Expertise for the Region

Unsurprisingly, enrollment success can vary from study-to-study, which is why it is vital for clinical trial sponsors to be selective about who they partner with for recruitment to their global studies. Specialized CROs with local, therapeutic and rescue trial expertise well positioned to leverage their regional disease treatment networks effectively are often more successful at connecting PIs to relevant studies for the patient population they serve most expediently and efficiently.

For example, mobilizing an expert Canadian team significantly enhances study start-up and overall performance for Sponsors’ oncology clinical trials in the country, especially in the case of a rescue. In keeping with the targets shared with its Sponsors, the Scimega team delivers consistent clinical trial start-up times 50% faster than the average for other countries on the continent, with trial sites often among top enrollers in global oncology studies.

Drug Developers want access to sites that can deliver on their promises of rapid FPI (first patient in study) and participant enrollment milestones. They need a CRO with established site relationships in Canada that can provide impeccable data, swift, accurate study feasibility and viability assessments, with strong CRAs in place with sites to further facilitate site start-up times.

Scimega is a Canadian niche oncology CRO that serves medium size and smaller biotech companies in clinical development of cutting-edge oncology therapies in Canada. A reliable partner for 29 years assisting cutting edge oncology biotech Sponsors with their global clinical trial programs and rescues. We consistently deliver our services with a strategic focus on Sponsor program success, and our team’s ability to engage oncologists and site teams at the highest level is unparalleled.

LEAN processes that ensure high-quality, and operations oversight of CRA activities and continuous internal QA activities is the gold standard with Scimega. And of course, our steady and high enrollment rates are a stand-out thanks to the selection of the right sites for your study design.

Scimega’s constant audit readiness and key performance metrics clearly reflects the caliber of combined skill and service our team of oncology experts consistently deliver.

What Sets Scimega Apart?

Our KPIs come out heads-and-shoulders above the industry averages in every area. These quantifiable attributes attained consistently over the years has contributed to our standing in the industry today. All possible because our solid team of oncology clinical trial experts is nurtured, supported and enhanced through our organizational values, processes, procedures, training, operations design, and leadership.

Our expertise is sought out for events, panels, and presentations to industry, to sites, to McGill university to help inform future oncologists about clinical trial research. Other CROs make referrals for our services and acknowledge our excellence. In global trails we are requested to take on additional tasks to pick up where others cannot provide the needed level of expertise or timely service. Which has led to us taking on new challenges that fall well within our capabilities to better serve our Sponsor’s requirements.

 

All this is in line with our commitment to devise innovative solutions specific to the unique challenges of each oncology clinical trial we monitor.

Largely, the future success of an increasingly more complex clinical trials industry to bring new products to market rests on the ability of sponsors and CROs, with their network of sties, to work together ever more effectively. Whereby all parties benefit from strong partnership established on a meeting of goals and ‘minds’ to forge win-win-win outcomes for the sponsor, the CRO, and the sites and patients served.

If you’re interested in learning more about the Canadian opportunity, we offer your real-time feasibility assessment in 2 weeks. Inquire now!

 

Contributed by: Julie Martin, President & CEO